Karyopharm Therapeutics Stock Today
| KPTI Stock | USD 6.42 0.28 4.56% |
PerformanceVery Weak
| Odds Of DistressHigh
|
Karyopharm Therapeutics is trading at 6.42 as of the 22nd of March 2025. This is a 4.56 percent increase since the beginning of the trading day. The stock's open price was 6.14. Karyopharm Therapeutics has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. The performance scores are derived for the period starting the 22nd of December 2024 and ending today, the 22nd of March 2025. Click here to learn more.
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. The company was incorporated in 2008 and is headquartered in Newton, Massachusetts. The company has 8.42 M outstanding shares of which 20.79 M shares are now shorted by private and institutional investors with about 11.06 trading days to cover. More on Karyopharm Therapeutics
Moving together with Karyopharm Stock
Moving against Karyopharm Stock
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Karyopharm Stock Highlights
| CEO President | Richard MBA |
| Thematic Idea | Cancer Fighters (View all Themes) |
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite Total, NASDAQ Composite, NASDAQ Health Care, Cancer Fighters, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) |
| Financial Strength | |
Karyopharm Therapeutics (KPTI) is traded on NASDAQ Exchange in USA. It is located in 85 Wells Avenue, Newton, MA, United States, 02459-3298 and employs 279 people. Karyopharm Therapeutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 51.67 M. Karyopharm Therapeutics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 8.42 M outstanding shares of which 20.79 M shares are now shorted by private and institutional investors with about 11.06 trading days to cover.
Karyopharm Therapeutics currently holds about 170.85 M in cash with (127.49 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.14.
Check Karyopharm Therapeutics Probability Of Bankruptcy
Ownership AllocationThe market capitalization of Karyopharm Therapeutics is $51.67 Million. 30% of Karyopharm Therapeutics outstanding shares are owned by institutional investors. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Consequently, institutional investors are subject to different rules and regulations than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or is about to change. Note, that even with negative profits, if the true value of the firm is larger than the current market value, you may still be able to generate positive returns on investment in this company.
Check Karyopharm Ownership Details
Karyopharm Therapeutics Risk Profiles
Investors will always prefer to have the highest possible return on investment while minimizing volatility. Karyopharm Therapeutics market risk premium is the additional return an investor will receive from holding Karyopharm Therapeutics long position in a well-diversified portfolio.
| Risk Adjusted Performance | (0.05) | |||
| Jensen Alpha | (0.43) | |||
| Total Risk Alpha | 0.0837 | |||
| Treynor Ratio | 1.46 |
Karyopharm Stock Against Markets
Karyopharm Therapeutics Corporate Management
| Reshma MD | Chief VP | Profile | |
| Kristin Abate | Chief VP | Profile | |
| James JD | Chief Officer | Profile | |
| Lisa DiPaolo | Executive Officer | Profile | |
| Sohanya MBA | Executive Officer | Profile |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Karyopharm Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. For more detail on how to invest in Karyopharm Stock please use our How to Invest in Karyopharm Therapeutics guide.You can also try the Stocks Directory module to find actively traded stocks across global markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Karyopharm Therapeutics. If investors know Karyopharm will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Karyopharm Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Karyopharm Therapeutics is measured differently than its book value, which is the value of Karyopharm that is recorded on the company's balance sheet. Investors also form their own opinion of Karyopharm Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Karyopharm Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Karyopharm Therapeutics' market value can be influenced by many factors that don't directly affect Karyopharm Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Karyopharm Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Karyopharm Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Karyopharm Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.